Prevalence And Clinical Significance Of Oncogenic CD79B And MYD88 Mutations In Primary Testicular Diffuse Large B-Cell Lymphoma: A Retrospective Study In China
Yan-ping Chen,1,2,* Long-feng Ke,3,* Jian-ping Lu,1 Jian-chao Wang,1,2 Wei-feng Zhu,1 Fang-fang Chen,3 Shao-feng Lin,4 Chun-wei Xu,3 Mei-juan Wu,5 Gang Chen1,2 1Department of Pathology of Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou 350014, People’s Republic of...
Main Authors: | Chen Y, Ke L, Lu J, Wang J, Zhu W, Chen F, Lin S, Xu C, Wu M, Chen G |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-11-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/prevalence-and-clinical-significance-of-oncogenic-cd79b-and-myd88-muta-peer-reviewed-article-OTT |
Similar Items
-
Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice
by: Carlo Visco, et al.
Published: (2020-10-01) -
Primary Type3 (Non-ABC, Non-GCB) Subtype of Extranodal Diffuse Large B-Cell Lymphoma of the Thyroid Bearing No MYD88 Mutation by Padlock Probe Hybridization
by: Yukiko Nishi, et al.
Published: (2017-06-01) -
Absence of Non-Canonical, Inhibitory MYD88 Splice Variants in B Cell Lymphomas Correlates With Sustained NF-κB Signaling
by: Yamel Cardona Gloria, et al.
Published: (2021-06-01) -
Follicular Lymphoma Presenting With Monoclonal IgM And MYD88 Mutation: A Case Report And Review Of The Literature
by: Xu L, et al.
Published: (2019-09-01) -
Response to ibrutinib of a refractory IgA lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation
by: Francesca Maria Quaglia, et al.
Published: (2019-08-01)